SecBot SecBot

FATE drug pipeline

FATE THERAPEUTICS INC · 2 rated drugs
$1.14
−10.9% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 2
Time to marketFT819 is in Phase 2 testing (RECLAIM-LN, a potentially registrational trial) that began enrolling in August 2026. If successful, an FDA submission could be several years away, likely in 2028-2029 at the earliest.

FT819 Updated Nov 13

What to watch

The next major catalyst for FT819 is the Phase 2 RECLAIM-LN interim data expected in H2 2027. Positive data would validate the registrational trial and could drive significant upside for this single-asset-focused biotech. Negative or mixed data would be bearish. The stock trades at $1.26 with a 52-week range of $0.95-3.23. The newly effective $100M ATM facility signals potential near-term dilution risk.

Bull case
  • FT819 is the first-ever iPSC-derived off-the-shelf CAR T-cell therapy, offering scalable manufacturing versus individualized autologous CAR-T. Phase 1 data across 36 patients in four autoimmune indications showed no dose-limiting toxicities, with 100% renal response at Month 6 in lupus nephritis patients. A Phase 2 potentially registrational trial (RECLAIM-LN) is underway with the first patient dosed in August 2026, supported by a $15M CIRM CLIN2 grant. Analyst consensus is bullish with a mean price target of $5.72 (327% upside) and 11 Buy/Strong Buy ratings.
● neutral
Impact
PhaseIND cleared / preclinical
Time to marketEarly preclinical/IND-stage; if clinical trials begin soon, a potential approval is likely 5+ years away, assuming successful Phase 1/2/3 development.

FT839 Updated Nov 13

What to watch

The next catalyst for FT839 is the initiation of its Phase 1/2 basket study and first patient dosed, which was projected for H2 2026 but has not yet been announced as of November 13, 2026. Watch for a press release on trial initiation; a positive outcome would de-risk the dual-target mechanism but remains a development-stage milestone with no efficacy data for at least 12-18 months. FATE's share price is far more dependent on FT819's Phase 2 RECLAIM-LN lupus nephritis readout than on FT839 progress.

Bull case
  • First-of-kind dual CD19/CD38-targeting CAR T could address a broader range of autoimmune conditions than single-target CAR Ts, differentiating FT839 from competitors.
  • Engineered to work without conditioning chemotherapy, which could dramatically expand the addressable patient population if confirmed in humans.
  • Built on Fate's proprietary iPSC platform, enabling an off-the-shelf (allogeneic) product with potentially lower cost and greater manufacturing scalability than personalized CAR Ts.
Bear case
  • FT839 is still at the preclinical/IND stage with no patients dosed; the dual-target mechanism has not been clinically validated and may face unexpected safety or efficacy hurdles.
  • FATE is a micro-cap stock trading near $1.28 with a ~52-week range of $0.95-$3.23; any clinical setback could disproportionately pressure the stock.
  • Fate Therapeutics carries significant cash-burn risk as a clinical-stage biotech with no approved products; FT839's development competes for resources with the lead program FT819.